keyword
MENU ▼
Read by QxMD icon Read
search

Absssi

keyword
https://www.readbyqxmd.com/read/28179245/ceftaroline-for-the-treatment-of-methicillin-resistant-staphylococcus-aureus-bacteremia
#1
Bryan Pinckney White, Katie E Barber, Kayla R Stover
PURPOSE: The utility of ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia (MRSAB) is reviewed. SUMMARY: Ceftaroline was originally approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs) but recently received an additional approval for the treatment of S. aureus bacteremia (SAB) associated with ABSSSIs. Ceftaroline has demonstrated efficacy for the treatment of MRSAB, including isolates with elevated minimum inhibitory concentrations to conventional therapy when used alone or in combination with other agents...
February 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28140693/pharmacokinetic-drug-evaluation-of-tedizolid-for-the-treatment-of-skin-infections
#2
Darrell McBride, Tamara Krekel, Kevin Hsueh, Michael J Durkin
Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Although tedizolid shares many similar properties with linezolid, another oxazolidinone used to treat ABSSSI, the two antibiotics have several key differences. Areas covered: This review provides a detailed summary of the overall pharmacodynamics, pharmacokinetics, clinical efficacy, and safety of tedizolid for the treatment of ABSSSI. Expert opinion: Compared to other antibiotics used for ABSSSI, tedizolid has several advantages...
January 31, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28131729/ceftaroline-fosamil-monotherapy-for-methicillin-resistant-staphylococcus-aureus-bacteremia-a-comparative-clinical-outcomes-study
#3
Samia Arshad, Vanthida Huang, Pamela Hartman, Mary B Perri, Daniela Moreno, Marcus J Zervos
OBJECTIVES: Vancomycin is the treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, its use has been subject to scrutiny due to failure in severe infections. Ceftaroline fosamil (CPT-F) is approved for MRSA acute bacterial skin and skin structure infections, but not for bloodstream infections. The clinical outcomes of treatment with CPT-F in patients with MRSA bacteremia were evaluated. METHODS: Patients diagnosed with MRSA bacteremia at Henry Ford Hospital in Detroit, Michigan, USA, involving isolates with a vancomycin minimum inhibitory concentration ≥1...
January 25, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28078655/single-dose-oritavancin-compared-to-standard-of-care-iv-antibiotics-for-acute-bacterial-skin-and-skin-structure-infection-in-the-outpatient-setting-a-retrospective-real-world-study
#4
Patrick J Anastasio, Pete Wolthoff, Annmarie Galli, Weihong Fan
INTRODUCTION: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs...
January 11, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28061827/systematic-review-and-network-meta-analysis-of-tedizolid-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-caused-by-mrsa
#5
Rachael McCool, Ian M Gould, Jacqui Eales, Teresa Barata, Mick Arber, Kelly Fleetwood, Julie Glanville, Teresa L Kauf
BACKGROUND: Tedizolid, the active moiety of tedizolid phosphate, is approved in the United States, the European Union, Canada and a number of other countries for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This network meta-analysis (NMA) evaluates the comparative effectiveness of tedizolid and other antibacterials indicated for the treatment of ABSSSI caused by MRSA...
January 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27993854/activity-of-omadacycline-and-comparator-agents-when-tested-against-staphylococcus-aureus-from-a-surveillance-program-conducted-in-north-america-and-europe
#6
Michael A Pfaller, Paul R Rhomberg, Michael D Huband, Robert K Flamm
Omadacycline is a new broad spectrum aminomethylcycline in late stage clinical development for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired pneumonia (CABP) as a once-daily formulation taken orally or intravenously. In this study, omadacycline and comparator agents were tested against 502 isolates of Staphylococcus aureus selected from a 2014 global surveillance program and compared to the results for 7,740 isolates from a 2010 surveillance program. For the 2014 isolates, testing was completed on 252 isolates from Europe (EU) and 250 isolates from North America (NA)...
December 19, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27988870/single-dose-dalbavancin-a-review-in-acute-bacterial-skin-and-skin-structure-infections
#7
Karly P Garnock-Jones
Intravenous dalbavancin (Dalvance(®), Xydalba(®)), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and tolerability as a single-dose regimen in the treatment of adult patients with ABSSSI. Single-dose dalbavancin is an effective and generally well tolerated treatment option for adults with ABSSSI, with noninferior efficacy to the two-dose dalbavancin regimen with regard to early clinical response (at 48-72 h) and low rates of adverse events...
January 2017: Drugs
https://www.readbyqxmd.com/read/27970803/cost-minimization-analysis-of-tedizolid-for-the-treatment-of-acute-bacterial-skin-and-skin-sub-structure-infections-absssi-in-greece
#8
R Insinga, E Dalakaki, M P Retsa, A Karokis, E M Sarpong
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27904526/new-agents-approved-for-treatment-of-acute-staphylococcal-skin-infections
#9
Jan Tatarkiewicz, Anna Staniszewska, Magdalena Bujalska-Zadrożny
Vancomycin has been a predominant treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections for decades. However, growing reservations about its efficacy led to an urgent need for new antibiotics effective against MRSA and other drug-resistant Staphylococcus aureus strains. This review covers three new anti-MRSA antibiotics that have been recently approved by the FDA: dalbavancin, oritavancin, and tedizolid. The mechanism of action, indications, antibacterial activity profile, microbial resistance, pharmacokinetics, clinical efficacy, adverse effects, interactions as well as available formulations and administration of each of these new antibiotics are described...
December 1, 2016: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/27736760/randomized-open-label-study-of-the-pharmacokinetics-and-safety-of-oral-and-intravenous-administration-of-omadacycline-to-healthy-subjects
#10
Haiying Sun, Lillian Ting, Surendra Machineni, Jens Praestgaard, Andreas Kuemmell, Daniel S Stein, Gangadhar Sunkara, Steven J Kovacs, Stephen Villano, S Ken Tanaka
Omadacycline is a first-in-class aminomethylcycline antibiotic with microbiological activity against Gram-positive and Gram-negative aerobes and anaerobes and atypical bacteria that is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). The bioavailability of a phase 3 tablet formulation relative to that obtained via intravenous (i.v.) administration (and of other oral formulations relative to that of the phase 3 tablet) was investigated in an open-label, randomized, four-period, crossover study with healthy subjects age 18 to 50 years...
December 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27665522/pooled-analysis-of-single-dose-oritavancin-in-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-caused-by-gram-positive-pathogens-including-a-large-patient-subset-with-methicillin-resistant-staphylococcus-aureus
#11
G Ralph Corey, Francis F Arhin, Matthew A Wikler, Daniel F Sahm, Barry N Kreiswirth, José R Mediavilla, Samantha Good, Claude Fiset, Hai Jiang, Greg Moeck, Heidi Kabler, Sinikka Green, William O'Riordan
Oritavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The phase 3 studies SOLO I and SOLO II demonstrated comparable efficacy and safety of a single dose of oritavancin compared with 7-10 days of twice-daily vancomycin in adults with acute bacterial skin and skin-structure infections (ABSSSIs). The present analysis assessed clinical responses by pathogen at 48-72 h and at study days 14-24 in SOLO patients within the pooled data set...
November 2016: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27598313/clinical-pathway-for-moderate-to-severe-acute-bacterial-skin-and-skin-structure-infections-from-a-us-perspective-a-roundtable-discussion
#12
John A Bosso, Anthony M Casapao, Jonathan Edwards, Kenneth Klinker, Christopher McCoy, David P Nicolau, Katherine K Perez, Andrew Marcarelli, Deeksha Dua
This article was written with the aim to establish a consensus clinical pathway for long-acting lipoglycopeptide antibiotics such as oritavancin (Orbactiv®) and dalbavancin (Dalvance®) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Seven infectious diseases pharmacy specialists from a variety of facilities across the United States (US) participated in a roundtable discussion to consider the use of newer single-dose long-acting lipoglycopeptides, and integrate them into clinical pathways for ABSSSI...
October 2016: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/27533787/tedizolid-and-linezolid-for-treatment-of-acute-bacterial-skin-and-skin-structure-infections-of-the-lower-extremity-versus-non-lower-extremity-pooled-analysis-of-two-phase-3-trials
#13
Warren S Joseph, Darren Culshaw, Steven Anuskiewicz, Carisa De Anda, Philippe Prokocimer
BACKGROUND: Tedizolid phosphate, the prodrug of the oxazolidinone tedizolid, has been approved in a number of countries, including the United States, those in the European Union, and Canada, for treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Two Phase 3 trials demonstrated the noninferior efficacy of tedizolid (200 mg once daily for 6 days) to linezolid (600 mg twice daily for 10 days) in patients with ABSSSI. Because of the challenges of treating lower-extremity ABSSSI, the efficacy and safety of tedizolid and linezolid for treating lower extremity versus non-lower extremity infections were compared...
August 17, 2016: Journal of the American Podiatric Medical Association
https://www.readbyqxmd.com/read/27530088/clinician-reported-lesion-measurements-in-skin-infection-trials-definitions-reliability-and-association-with-patient-reported-pain
#14
John H Powers, Anita F Das, Carisa De Anda, Philippe Prokocimer
OBJECTIVES: Outcome assessments as clinical trial endpoints should be well-defined, reliable, and reflect meaningful treatment benefits. For acute bacterial skin and skin structure infections (ABSSSI) trials, recent recommendations suggest a primary endpoint of reduction in skin lesion area. Objectives were: evaluate ABSSSI lesion area measurement reliability, evaluate impact of various lesion area definitions on treatment effect size, and explore relationships between lesion area and pain...
September 2016: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/27524636/anti-infective-dosing-for-obese-adult-patients-a-focus-on-newer-drugs-to-treat-methicillin-resistant-staphylococcus-aureus-acute-bacterial-skin-and-skin-structure-infections
#15
REVIEW
Manjunath P Pai
PURPOSE: Obesity is recognized to be a risk factor for acute bacterial skin and skin structure infections (ABSSSIs) that are associated with methicillin-resistant Staphylococcus aureus (MRSA). Several new antimicrobial agents have been introduced to treat MRSA-related ABSSSI and are dosed with and without regard to weight. This review seeks to explain the pharmacokinetic and pharmacodynamic (PK-PD) rationale for initial and maintenance dosage selection of these newer agents in obese adults...
September 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27510635/population-pk-modeling-and-target-attainment-simulations-to-support-dosing-of-ceftaroline-fosamil-in-pediatric-patients-with-acute-bacterial-skin-and-skin-structure-infections-and-community-acquired-bacterial-pneumonia
#16
Todd A Riccobene, Tatiana Khariton, William Knebel, Shampa Das, James Li, Alena Jandourek, Timothy J Carrothers, John S Bradley
Ceftaroline, the active form of the prodrug ceftaroline fosamil, is approved for use in adults with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infections (ABSSSI) in the United States and for similar indications in Europe. Pharmacokinetic (PK) data from 5 pediatric (birth to <18 years) studies of ceftaroline fosamil were combined with PK data from adults to update a population PK model for ceftaroline and ceftaroline fosamil. This model, based on a data set including 305 children, was used to conduct simulations to estimate ceftaroline exposures and percentage of time that free drug concentrations were above the minimum inhibitory concentration (%fT>MIC) for pediatric dose regimens...
March 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27469981/discovery-pharmacology-and-clinical-profile-of-omadacycline-a-novel-aminomethylcycline-antibiotic
#17
S Ken Tanaka, Judith Steenbergen, Stephen Villano
Omadacycline is novel, aminomethyl tetracycline antibiotic being developed for oral and intravenous (IV) administration for the treatment of community-acquired bacterial infections. Omadacycline is characterized by an aminomethyl substituent at the C9 position of the core 6-member ring. Modifications at this position result in an improved spectrum of antimicrobial activity by overcoming resistance known to affect older generation tetracyclines via ribosomal protection proteins and efflux pump mechanisms. In vitro, omadacycline has activity against Gram-positive and Gram-negative aerobes, anaerobes, and atypical pathogens including Legionella and Chlamydia spp...
December 15, 2016: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/27401576/critical-role-of-alpha-toxin-and-protective-effects-of-its-neutralization-by-a-human-antibody-in-acute-bacterial-skin-and-skin-structure-infections
#18
Vien T M Le, Christine Tkaczyk, Sally Chau, Renee L Rao, Etyene Castro Dip, Eliane P Pereira-Franchi, Lily Cheng, Sally Lee, Holly Koelkebeck, Jamese J Hilliard, Xiang Qing Yu, Vivekananda Datta, Vien Nguyen, William Weiss, Laszlo Prokai, Terrence O'Day, C Kendall Stover, Bret R Sellman, Binh An Diep
Methicillin-resistant Staphylococcus aureus (MRSA) causes large-scale epidemics of acute bacterial skin and skin structure infections (ABSSSI) within communities across the United States. Animal models that reproduce ABSSSI as they occur in humans are urgently needed to test new therapeutic strategies. Alpha-toxin plays a critical role in a variety of staphylococcal infection models in mice, but its role in the pathogenesis of ABSSSI remains to be elucidated in rabbits, which are similar to humans in their susceptibility to S...
October 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27370913/single-dose-oritavancin-treatment-of-acute-bacterial-skin-and-skin-structure-infections-solo-trial-efficacy-by-eron-severity-and-management-setting
#19
Daniel H Deck, Jennifer M Jordan, Thomas L Holland, Weihong Fan, Matthew A Wikler, Katherine A Sulham, G Ralph Corey
INTRODUCTION: Introduction of new antibiotics enabling single-dose administration, such as oritavancin may significantly impact site of care decisions for patients with acute bacterial skin and skin structure infections (ABSSSI). This analysis compared the efficacy of single-dose oritavancin with multiple-dose vancomycin in patients categorized according to disease severity via modified Eron classification and management setting. METHODS: SOLO I and II were phase 3 studies evaluating single-dose oritavancin versus 7-10 days of vancomycin for treatment of ABSSSI...
September 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27354817/focus-on-jnj-q2-a-novel-fluoroquinolone-for-the-management-of-community-acquired-bacterial-pneumonia-and-acute-bacterial-skin-and-skin-structure-infections
#20
REVIEW
Travis M Jones, Steven W Johnson, V Paul DiMondi, Dustin T Wilson
JNJ-Q2 is a novel, fifth-generation fluoroquinolone that has excellent in vitro and in vivo activity against a variety of Gram-positive and Gram-negative organisms. In vitro studies indicate that JNJ-Q2 has potent activity against pathogens responsible for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), such as Staphylococcus aureus and Streptococcus pneumoniae. JNJ-Q2 also has been shown to have a higher barrier to resistance compared to other agents in the class and it remains highly active against drug-resistant organisms, including methicillin-resistant S...
2016: Infection and Drug Resistance
keyword
keyword
15671
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"